摘要
目的探讨帕金森病(PD)患者伴发高同型半胱氨酸血症(HHcy)情况及美多巴对其血清同型半胱氨酸(Hcy)水平的影响。方法选择2006-06-01-2009-12-31入住作者医院的PD患者53例,按入院前是否服用美多巴治疗分为非美多巴组和美多巴组,两组患者入院后均予美多巴口服治疗;另选择31名同期健康体检者为对照。采用荧光偏振免疫分析法(FPIA)检测血清Hcy水平,微粒子酶免分析法(MEIA)检测血清叶酸(FA)及维生素B12(VitB12)水平。收集患者初次就诊及初次复诊时的血清Hcy、FA、VitB12水平资料至2010-01-30,并进行分析比较。结果 (1)初次就诊时非美多巴组和美多巴组PD患者血清Hcy水平〔分别(17.28±6.79)、(18.50±6.56)μmol/L〕均高于健康对照组〔(13.49±3.21)μmol/L〕(均P<0.01),HHcy的比例〔分别为50%(14/28)和76%(19/25)〕亦高于健康对照组〔29%(9/31)〕(均P<0.01),而血清FA、VitB12的水平无统计学差异(均P>0.05)。HHcy患者的血清Hcy水平与FA、VitB12水平无相关性(分别r=0.118,P=0.455;r=0.001,P=0.995)。(2)非美多巴组患者复诊时血清Hcy水平〔(15.84±3.33)μmol/L〕较治疗前〔(12.92±3.15)μmol/L〕升高(P<0.05),血清FA、VitB12水平同治疗前比较无统计学差异(P>0.05)。美多巴组患者服用美多巴治疗后血清Hcy、FA、VitB12水平同初次就诊时比较均无统计学差异(均P>0.05)。结论服用美多巴可能使PD患者血清Hcy水平升高,但可能不是PD患者伴有HHcy的惟一原因。
Objective To explore the occurrence of hyperhomocysteine （HHcy） in patients with Parkinson disease （PD） and the effect of madopar on serum Hcy level. Methods Fifty-three PD patients, who were accepted in our hospital from 2006-06-01 to 2009-12-31, were divided into non-madopar-treated group and madopar-treated group, based on whether madopar was taken previously. Both groups of patients were treated by madopar after hospitalization. Thirty-one healthy controls were also included in this study. Fluorescence polarization immunoassay （FPIA） was applied to test serum Hcy level and microparticle enzyme immunoassay analysis （MEIA） was used to measure FA and VitB12 levels. The serum levels of Hcy, FA and VitB12 in PD patients＇ first visit and first return visit and those in healthy controls were collected. Results （1） The Hcy levels of first test in non-madopar-treated group [- （17.28 ± 6.79） μmol/L] and in madopar-treated group [ （18.50±6.56） μmol/L] were both higher than that in the control group [ （13.49±3.21） μmol/L] （P〈0. 01）, the occurrence of HHcy in non-madopar and madopar PD groups were 50% and 76%, respectively, and both were higher than that in the control group （29%, P〈0.01）. No significant differences of FA and VitB12 levels were found among these three groups （P〉0.05） . There was no significant correlation between the serum Hcy level and FA or VitB12 level （r=0. 118, P=0. 455; r=0. 001, P=0. 995, respectively） . （2） Twenty cases of 53 had return visits, including 10 cases of non-madopar-treated patients and 10 madopar-treated patients, and the interval between their first visit and first return visit was 1-27 and 5-25 months, respectively, with the median of 8.5 and 11 months, respectively. Compared with the pre-treated [ （12.92±3.15） μmol/L], the Hcy level [（15.84±3.33） μmol/L] of the return visits increased in non-madopar-treated group （P〈0. 05）, while the FA and VitB12 levels had no significant change （P〉0.05）. No significant difference was found in the serum Hey and FA, VitB12 levels between the first visit and first return visit in madopar continually treatment group （P〉 0. 05） . Conclusions The Hcy level could be increased after madopar treatment in PD patient, however, madopa may not be the unique factor for HHcy.
出处
《中国神经免疫学和神经病学杂志》
CAS
2011年第1期17-19,共3页
Chinese Journal of Neuroimmunology and Neurology
